BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will present at the J.P. Morgan 2026 Healthcare Conference on January 14, 2026. Presentation DetailsDate: Wednesday, January 14, 2026 Time: 7:30 AM PT Webcast Link: cmpx.info/jpmorgan Virtual/Replay availability: The presentation will be archived on Compass’ Events page. Investors ...

Pfizer’s Tukysa, when given as part of the initial treatment for an advanced form of breast cancer, delayed tumor growth by more than eight months, according to a study that may expand its use https://t.co/XjpGcBOHzS ...

Core Viewpoint - Compass Therapeutics, Inc. is actively engaging with investors through participation in key healthcare conferences in December 2025, highlighting its focus on oncology and proprietary antibody-based therapeutics [1][2]. Group 1: Upcoming Investor Events - Compass Therapeutics will participate in the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, at 8:00 AM ET in New York, NY [2]. - The company will also attend the 8th Annual Evercore Healthcare Conference on December 4, 2025, at 10:00 AM ET in Coral Gables, FL [2]. - Presentations from these events will be archived for 90 days on Compass' Events page, allowing for virtual/replay availability [2]. Group 2: Company Overview - Compass Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary antibody-based therapeutics for oncology [4]. - The company’s research emphasizes the interplay between angiogenesis, the immune system, and tumor growth, aiming to create a robust pipeline of novel product candidates [4]. - The therapeutic strategies include targeting angiogenesis, inducing immune responses, and overcoming immunosuppressive mechanisms utilized by tumors [4]. - Founded in 2014, Compass Therapeutics is headquartered in Boston, Massachusetts [4].